Haptoglobin Glycan Analysis for Hepatocellular Carcinoma Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hepatocellular carcinoma (HCC) are inadequate for early detection, particularly due to poor sensitivity and specificity of existing biomarkers like AFP and PIVKA-II, and the limitations of imaging techniques.
Innovation Solution
The analysis of specific glycan structures attached to the β-chain of haptoglobin, particularly at position N184, is used to aid in the detection of HCC. This involves determining the amount of specific glycan structures, such as HexNAc(5)Hex(6)Fuc(1)NeuAc(2), in patient samples and comparing them to reference amounts, with altered amounts indicating HCC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If imaging techniques (ultrasound, CAT scan, MRI) are used for HCC detection, then detection capability is improved, but cost increases and sensitivity for early stage tumors remains poor
Solution Approach 1:
The invention changes the detection parameter from imaging-based physical detection to biochemical detection using glycan structure analysis. By analyzing specific glycan structures (e.g., HexNAc(5)Hex(6)Fuc(1)NeuAc(2)) attached to haptoglobin at position N184, the method achieves high sensitivity for early HCC detection without requiring expensive imaging equipment.
2Measurement precision
If AFP and PIVKA-II biomarkers are used for HCC detection, then detection capability is improved, but sensitivity and specificity remain limited
Solution Approach 1:
The invention combines multiple detection targets into a composite diagnostic approach: analyzing specific glycan structures attached to haptoglobin in combination with traditional biomarkers AFP and PIVKA-II. This composite approach leverages the advantages of each marker while compensating for their individual limitations, achieving superior diagnostic accuracy through multi-parameter detection.
Solution Approach 2:
The invention focuses on a specific local characteristic of haptoglobin - the glycan structures at position N184 - rather than analyzing the entire protein or using non-specific markers. By targeting the specific glycan motif HexNAc(5)Hex(6)Fuc(1)NeuAc(2) at this precise location, the method achieves high specificity for HCC detection.
3Productivity
If ultrasound detection is used for HCC screening, then screening capability is improved, but prognosis value deteriorates due to poor sensitivity for small tumors
Solution Approach 1:
The invention replaces the mechanical imaging system (ultrasound waves requiring tumor mass to reflect sound) with a biochemical detection system that can identify molecular markers at much lower concentrations. The glycan structure analysis can detect HCC at the molecular level before tumors become large enough for ultrasound detection, thereby improving prognosis value while maintaining screening capacity.
Data Source
AI summary
The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and/or PIVKA-II in the detection of HCC.